NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Harrow, Inc. HROW
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$272.3M
▲ 36.4% vs FY2024
EPS · FY25
$-0.14
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-8.4%
Net margin · FY25
-1.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 272.3M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 2 cents on every revenue dollar this year.
Per share
USD -0.14
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-8.4%
Return on equity, FY2025
ROE
Operating margin11.2%
Net margin-1.9%
Return on assets-1.3%
Each USD of equity lost 8 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+41.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+45.4%
+41.0%
+39.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+44.6%
Change, 10 years—
The share count grew 45% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 399.5M
total assets, end of FY2025
Total assetsUSD 399.5M
EquityUSD 52.4M
CashUSD 72.9M
Gross debtUSD 250.0M
Net debtUSD 177.1M
Current ratio2.20×
Net debt stands at 338% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.3
0.2
0.1
0.1
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
−0.0
0.0
0.0
·
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.14
−0.49
−0.75
−0.51
−0.69
−0.13
0.01
0.61
−0.60
−1.50
−1.66
−1.11
−0.88
−1.24
−2.65
−0.16
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−8.4
−24.9
−49.6
−72.5
−93.6
−12.2
0.6
106.9
−264.9
−756.4
−470.0
−87.0
−60.9
−129.8
·
·
−176.9
−82.0
−122.7
Shares out B
0.04
0.04
0.04
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.00
0.02
·
·
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed